药物组合突破：Paxalisib，Pembrolizumab和化学疗法在乳腺癌临床试验中表现出希望

1B期试验的早期结果表明，药物组合可显着降低转移性三阴性乳腺癌中循环的肿瘤细胞，从而提供新的希望。

Drug Combo Breakthrough: Paxalisib, Pembrolizumab, and Chemo Show Promise in Breast Cancer Clinical Trial

药物组合突破：Paxalisib，Pembrolizumab和化学疗法在乳腺癌临床试验中表现出希望

The landscape of breast cancer treatment is constantly evolving, and recent news from a Phase 1b clinical trial is generating excitement. This trial explores a novel drug combination—Paxalisib, pembrolizumab (Keytruda®), and standard chemotherapy—for metastatic triple-negative breast cancer.

乳腺癌治疗的景观在不断发展，而1B期临床试验的最新消息正在引起兴奋。该试验探讨了一种新型药物组合 - 帕氏菌，pembrolizumab（KeyTruda®）和标准化疗 - 用于转移性三阴性乳腺癌。

Early Optimism: A Glimpse of Hope

早期乐观：希望

Kazia Therapeutics announced encouraging preliminary results from the first patient in their Phase 1b trial. The 61-year-old woman with metastatic triple-negative breast cancer experienced a greater than 50% reduction in circulating tumor cells (CTCs) and a notable decrease in CTC clusters after just one cycle (21 days) of the investigational regimen.

Kazia Therapeutics在其1B期试验中宣布了第一位患者的初步结果。这位61岁的患有三阴性乳腺癌的妇女的循环肿瘤细胞（CTC）降低了50％以上，并且在研究方案的一（21天）之后，CTC簇的CTC簇降低了显着降低。

Why This Matters: Targeting Metastasis

为什么这很重要：针对转移

CTC clusters are known to be significant drivers of metastasis, resisting apoptosis, evading immune detection, and efficiently seeding new tumor sites. Standard chemotherapy can sometimes transiently increase CTCs, while immunotherapy alone may have delayed or modest effects. The rapid reduction in both CTC numbers and clusters with this drug combo is a potentially significant improvement.

众所周知，CTC簇是转移的重要驱动因素，可抵抗凋亡，逃避免疫检测并有效地播种新的肿瘤部位。标准化疗有时会瞬时增加CTC，而仅免疫疗法可能会延迟或适度的影响。通过这种药物组合，CTC数量和簇的快速减少是一种潜在的显着改善。

The Science Behind the Success

成功背后的科学

These early clinical data mirror preclinical findings published in Molecular Cancer Therapeutics, highlighting Paxalisib's ability to disrupt both single CTCs and multicellular clusters when combined with immunotherapy. This reflects a synergistic effect, potentially offering a more effective early intervention against systemic disease progression.

这些早期的临床数据镜面临床前发现在分子癌治疗剂中发表，强调了帕萨西比（Paxalisib）与免疫疗法结合使用时破坏单个CTC和多细胞簇的能力。这反映了一种协同作用，有可能提供更有效的早期干预，以防止全身性疾病进展。

Looking Ahead: What's Next for the Clinical Trial?

展望未来：临床试验的下一步是什么？

Kazia Therapeutics is moving forward with several key steps:

Kazia Therapeutics正在采取多个关键步骤前进：

• Exploring the relationship between CTC kinetics and radiographic responses.
• Continuing enrollment in the Phase 1b study to assess safety, tolerability, and pharmacodynamics.
• Conducting a comprehensive analysis of the immune microenvironment and CTC kinetics across all patients.
• Monitoring long-term outcomes, including imaging, progression-free survival, and correlation with molecular biomarkers.

A New York State of Mind: Cautious Optimism

纽约的心态：谨慎的乐观

While it's only one patient, the early results are undeniably exciting. Dr. John Friend, CEO of Kazia Therapeutics, expressed strong optimism, emphasizing the potential of this combination to offer a meaningful early intervention against systemic disease progression. Of course, more data is needed to confirm these initial findings and determine the long-term efficacy and safety of this drug combo. But for now, it's a reason to feel a little bit brighter about the future of breast cancer treatment.

虽然只有一名患者，但早期的结果无可否认是令人兴奋的。 Kazia Therapeutics首席执行官John Friend博士表达了强烈的乐观情绪，强调了这种组合的潜力，即提供有意义的早期干预，以防止全身性疾病进展。当然，需要更多数据来确认这些初始发现并确定该药物组合的长期功效和安全性。但是目前，这是一个让乳腺癌治疗的未来更明亮的原因。